Key result
Higher soluble ST2 linked to ~28% higher cardiovascular event risk per doubling in adults with CHD.
Why the study?
Soluble suppression of tumourigenicity-2 is upregulated in response to myocardial stress, but its release and association with cardiovascular events in ACHD required investigation.
Does soluble ST2 level predict cardiovascular events in adults with congenital heart disease?
Cohort (n=590)
No
Does soluble ST2 level predict cardiovascular events in adults with congenital heart disease?
sST2 is a promising biomarker for risk stratification in adults with congenital heart disease, particularly in women and those with complex disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in congenital heart disease; hypothesis-generating for sST2 in risk stratification.
OBJECTIVE: Soluble suppression of tumourigenicity-2 (sST2) is upregulated as response to myocardial stress and may be a potential biomarker for risk stratification in patients with adult congenital heart disease (ACHD). This study aimed to investigate the release of sST2 and its association with cardiovascular events in ACHD. METHODS: In this prospective cohort study, 602 consecutive patients with ACHD visiting the outpatient clinic were included (2011-2013). The association between sST2 and a primary composite endpoint of all-cause mortality, heart failure, hospitalisation, arrhythmia, thromboembolic events or cardiac interventions was investigated using multivariable Cox regression. RESULTS: sST2 was measured in 590 (98%) patients (median age 33 [25-41] years, 42% women). After a median follow-up of 5.8 [IQR 5.1-6.2) years, 225 (38.5%) reached the primary endpoint. sST2 was significantly associated with the primary endpoint when adjusted for age, sex, creatinine and N terminal pro-B type brain natriuretic peptide (NT-proBNP) (HR per twofold higher sST2: 1.28, 95% CI 1.03 to 1.58, p=0.025). This association negated when adjusted for clinical variables and NT-proBNP (HR per twofold higher sST2: 1.19, 95% CI 0.96 to 1.48, p=0.106). Stratified analysis in complex ACHD did show a significant association between sST2 and the primary endpoint when adjusted for clinical variables and NT-proBNP (HR per twofold higher sST2: 1.31, 95% CI 1.01 to 1.69, p=0.043). Sex-specific analysis showed an association between sST2 and the primary endpoint in women (HR per twofold higher sST2 1.80, 95% CI 1.30 to 2.49, p<0.001) but not in men (HR per twofold higher sST2 1.19, 95% CI 0.90 to 1.56, p=0.223). CONCLUSIONS: sST2 is a promising novel biomarker in patients with ACHD, specifically in complex ACHD and women. Future research is warranted to elucidate sex-specific and diagnosis-specific differences.
No takes yet. Share an insight, caveat, or question.
Geenen et al. (2019) conducted a cohort in Adult congenital heart disease (ACHD) (n=590). Soluble suppression of tumourigenicity-2 (sST2) (per twofold higher value) vs. Lower sST2 levels was evaluated on Composite of all-cause mortality, heart failure, hospitalisation for cardiac reasons, arrhythmia, thromboembolic events, or cardiac interventions (HR 1.28, 95% CI 1.03 to 1.58, p=0.025). Soluble ST2 was associated with an increased risk of adverse cardiovascular events per twofold higher level in adults with congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: